...
首页> 外文期刊>Headache >A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
【24h】

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)

机译:舒马曲坦散剂(AVP-825)的呼吸动力鼻腔给药治疗急性偏头痛的随机,双盲,安慰剂对照研究(TARGET研究)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

ObjectiveTo evaluate the efficacy and safety of AVP-825, a drug-device combination of low-dose sumatriptan powder (22mg loaded dose) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine headache.
机译:目的评估低剂量舒马曲坦粉剂(22mg负荷剂量)通过靶向呼吸动力设备与含乳糖粉的相同设备(安慰剂设备)经鼻腔给药的药物设备组合AVP-825的疗效和安全性偏头痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号